The European Commission has granted an expanded approval to ravulizumab-cwvz to include children with a body weight of at least 10 kg, as well as adolescents, with paroxysmal nocturnal hemoglobinuria.
Gina Mauro
Advertisement
Articles by Gina Mauro
Advertisement
Latest Updated Articles
Approval in Paroxysmal Nocturnal Hemoglobinuria With Pediatric IndicationPublished: September 9th 2021 | Updated:
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Meta-analysis finds vegetarian and vegan diets can support healthy growth in children
2
FDA calls for improved retail recall compliance to protect infants and young children
3
Mimi C. Lee, MD, PhD, breaks down GeneDx's ExomeDx and GenomeDx tests
4
FDA approves Nuzolvence (zoliflodacin) for treatment of uncomplicated urogenital gonorrhea in 12 years and up
5
